



## Notice of Revisions to Earnings Forecasts for the Fiscal Year Ending March 31, 2025

**OSAKA, Japan, October 28, 2024** - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that it has made the following revisions to its consolidated earnings forecasts for the full year ending on March 31, 2025. The prior earnings forecasts were released on May 13, 2024.

### 1. Revisions to consolidated earnings forecasts

Revisions to consolidated forecasts for the fiscal year ending March 31, 2025 (April 1, 2024 – March 31, 2025)

(Millions of yen)

	Revenue	Operating profit	Profit before tax	Profit attributable to owners of parent	Basic earnings per share (yen)*
Previous forecasts (A)	455,000	160,000	200,000	163,000	191.66
Revised forecasts (B)	460,000	165,000	206,000	171,000	201.03
Change (B-A)	+ 5,000	+ 5,000	+ 6,000	+ 8,000	—
Change (%)	+ 1.1	+ 3.1	+ 3.0	+ 4.9	—
[Reference]					
Results for the fiscal year ended March 31, 2024	435,081	153,310	198,283	162,030	186.17
Y on Y change (%)	+ 5.7	+ 7.6	+ 3.9	+ 5.5	—

\* SHIONOGI conducted a 3-for-1 stock split of shares of common stock, effective October 1, 2024. Basic earnings per share was calculated under the assumption that the stock split had been conducted at the beginning of the year ended March 31, 2024.

### 2. Reasons for revisions to consolidated earnings forecasts

During the second quarter consolidated cumulative period, we exceeded our performance forecasts in terms of revenue and all profit items. Overseas business achieved steady sales, particularly driven by cefiderocol. Regarding the HIV business, we saw continued growth in royalty income and dividends from ViiV Healthcare, with sales growth centered on Cabenuva, Apretude, and Dovato. Regarding the domestic business, the revenue from infectious disease drugs fell short of expectations due to a significant decrease in the number of influenza and COVID-19 cases compared to the same period last year. However, the influenza treatment Xofluza and the COVID-19 treatment Xocova have each attained the target market share in their respective treatment markets, and their shares continue to increase. Therefore, it is expected that they will contribute steadily to performance. Additionally, from the third quarter onwards, we will pursue expanded sales activities

in the QOL disease area, less affected by epidemics, as a new revenue base. In particular, the insomnia treatment, Quviviq® tablets (generic name: daridorexant, hereinafter referred to as Quviviq), for which we signed a sales partnership agreement with Nxera Pharma Japan Co., Ltd. is expected to contribute meaningfully.<sup>1</sup>

Reflecting the favorable trends in the overseas business and HIV business, as well as the expected contribution of Quviviq, we revised our forecast upwards.

Note: The forecasts shown in the material herein are based on currently available information as of October 28, 2024. Actual performance may differ materially from these forecasted figures due to various factors in the future.

### **Forward-Looking Statements**

*This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.*

### **Reference**

1. [Press release on October 1, 2024](#)  
Regarding the Conclusion of Sales Partnership Agreement with Nxera Pharma Japan for the Insomnia Treatment "QUVIVIQ®"

### **For Further Information, Contact:**

SHIONOGI Website Inquiry Form: <https://www.shionogi.com/global/en/contact.html>